A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Cannabidiol (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Registrational; Therapeutic Use
- Sponsors INSYS Pharma
- 31 Jul 2017 Planned initiation date changed from 31 Aug 2017 to 30 Sep 2017.
- 31 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 31 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.